Advertisement
Advertisement

INO

INO logo

Inovio Pharmaceuticals, Inc.

1.75
USD
+0.03
+1.51%
Apr 17, 15:59 UTC -4
Closed
exchange

After-Market

1.75

0.00
+0.17%

Inovio Pharmaceuticals, Inc. Profile

About

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Info & Links

CEO

Jacqueline E. Shea

Headquarters

660 W. GERMANTOWN PIKE, SUITE 110
PLYMOUTH MEETING, PA 19462, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.inovio.com

Auditor

Ernst & Young LLP

Share holders

65

Employees

134

Inovio Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization2

64.14M

Enterprise Value

-1.67M

Enterprise Value/EBITDA(ttm)

0.02

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

69.64

Price to Book(mrq)

0.78

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-12139.92%

Return on Equity(ttm)

-118.17%

Return on Invested Capital(ttm)

-128.10%

Return on Assets(ttm)

-83.47%

Income Statement

Revenue(ttm)

217.80K

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

217.80K

EBITDA(ttm)3

-109.27M

Net Income Available to Common(ttm)

-107.25M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

0.89

52-Week Change

-82.88%

S&P 500 52-Week Change

5.43%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

36.67M

Dividend Yield

0.00%

Float4

25.45M

% Held by Insiders

2.50%

% Held by Institutions

26.79%

Balance Sheet

Total Cash(mrq)

94.11M

Total Cash Per Share(mrq)

2.57

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.77%

Quick Ratio(mrq)

3.88%

Book Value Per Share(mrq)

1.90

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.83

Free Cash Flow(ytd)

-104.51M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement